Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate Mofetil vs Azathioprine in PBC-AIH Overlap Syndrome
NCT04933292Phase 4Unknown
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mycophenolate mofetil in Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (AIH-PBC) (2 arms). Primary endpoint: Biochemical remission at 6 months. Status: unknown.
02
Drugs
mycophenolate mofetil
03
Conditions
Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (AIH-PBC)
Beyond the preview
Go deeper on NCT04933292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04933292.